Mark J Levis


1992 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
fms-Like Tyrosine Kinase 3 Medicine & Life Sciences
4'-N-benzoylstaurosporine Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Chemotherapy Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2018

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation

Fathi, A. T. , Blonquist, T. M. , Hernandez, D. , Amrein, P. C. , Ballen, K. K. , McMasters, M. , Avigan, D. E. , Joyce, R. , Logan, E. K. , Hobbs, G. , Brunner, A. M. , Joseph, C. , Perry, A. M. , Burke, M. , Behnan, T. , Foster, J. , Bergeron, M. K. , Moran, J. A. , Ramos, A. Y. , Som, T. T. & 6 others Rae, J., Fishman, K. M., McGregor, K. L., Connolly, C., Neuberg, D. S. & Levis, M. J. Jan 15 2018 In : Cancer. 124, 2, p. 306-314 9 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Maximum Tolerated Dose

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Cortes, J. , Perl, A. E. , Döhner, H. , Kantarjian, H. , Martinelli, G. , Kovacsovics, T. , Rousselot, P. , Steffen, B. , Dombret, H. , Estey, E. , Strickland, S. , Altman, J. K. , Baldus, C. D. , Burnett, A. , Krämer, A. , Russell, N. , Shah, N. P. , Smith, C. C. , Wang, E. S. , Ifrah, N. & 4 others Gammon, G., Trone, D., Lazzaretto, D. & Levis, M. Jan 1 2018 (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Febrile Neutropenia

Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase–driven leukemias and other malignancies

Bruner, J. K., Ma, H. S., Li, L., Qin, A. C. R., Rudek, M. A., Jones, R. J., Levis, M. J., Pratz, K. W., Pratilas, C. A. & Small, D. Oct 15 2017 In : Cancer Research. 77, 20, p. 5554-5563 10 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Mitogen-Activated Protein Kinase Kinases

Advances in targeted therapy for acute myeloid leukaemia

Kayser, S. & Levis, M. J. Jan 1 2017 (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Drug Therapy
Chromosome Aberrations
Protein-Tyrosine Kinases

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I. , Beumer, J. H. , Pratz, K. W. , McDevitt, M. A. , Baer, M. R. , Blackford, A. L. , Smith, B. D. , Gore, S. D. , Carraway, H. E. , Showel, M. M. , Levis, M. J. , Dezern, A. E. , Gladstone, D. E. , Ji, J. J. , Wang, L. , Kinders, R. J. , Pouquet, M. , Ali-Walbi, I. , Rudek, M. A. , Poh, W. & 5 others Herman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J. E. Feb 1 2017 In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia